The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C

Authors Information
Article Notes and Dates
To Cite : Kadjbaf D, Keshvari M, Alavian S M, Pouryasin A, Behnava B, et al. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C, Hepat Mon. 2016 ;16(6):e37011. doi: 10.5812/hepatmon.37011.
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011; 26 Suppl 1: 83-95[DOI][PubMed]
  • 2. Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, et al. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a +/- ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. J Gastroenterol. 2014; 49(3): 492-501[DOI][PubMed]
  • 3. Goedert JJ, Second Multicenter Hemophilia Cohort S. Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. Haemophilia. 2005; 11(5): 516-28[DOI][PubMed]
  • 4. Assarehzadegan MA, Ghafourian Boroujerdnia M, Zandian K. Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran. Iran Red Crescent Med J. 2012; 14(8): 470-4[PubMed]
  • 5. Mansour-Ghanaei F, Fallah MS, Shafaghi A, Yousefi-Mashhoor M, Ramezani N, Farzaneh F, et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Med Sci Monit. 2002; 8(12)-800[PubMed]
  • 6. Assarehzadegan MA, Shakerinejad G, Noroozkohnejad R, Amini A, Rahim Rezaee SA. Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl. 2009; 20(4): 681-4[PubMed]
  • 7. Vossughinia H, Goshayeshi L, Bayegi HR, Sima H, Kazemi A, Erfani S, et al. Prevalence of hepatitis C virus genotypes in mashhad, northeast iran. Iran J Public Health. 2012; 41(9): 56-61[PubMed]
  • 8. Silva LK, Silva MB, Lopes GB, Rodart IF, Costa FQ, Santana NP, et al. Prevalence of hepatitis C virus infection and HCV genotypes among hemophiliacs in the State of Bahia, Northeastern Brazil: analysis of serological and virological parameters. Rev Soc Bras Med Trop. 2005; 38(6): 496-502[PubMed]
  • 9. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat. 2002; 9(5): 390-2[PubMed]
  • 10. Djebbi A, Bahri O, Langar H, Sadraoui A, Mejri S, Triki H. Genetic variability of genotype 1 hepatitis C virus isolates from Tunisian haemophiliacs. New Microbiol. 2008; 31(4): 473-80[PubMed]
  • 11. Hajia M, Amirzargar A, Khedmat H, Shahrokhi N, Farzanehkhah M, Ghorishi S, et al. Genotyping Pattern among Iranian HCV Positive Patients. Iran J Public Health. 2010; 39(2): 39-44[PubMed]
  • 12. Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013; 13(1)
  • 13. Hamidi-Fard M. Hepatitis C Genotypes in Hemophilia Patients in Iran. IRCMJ. 2011; 2011(2, Feb): 148
  • 14. Zarkesh-Esfahani SH, Kardi MT, Edalati M. Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J. 2010; 7: 69[DOI][PubMed]
  • 15. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007; 13(2): 156-63[DOI][PubMed]
  • 16. Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol. 2012; 157(10): 1959-65[DOI][PubMed]
  • 17. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009; 49(10): 2195-9[DOI][PubMed]
  • 18. Keshvari M, Alavian SM, Behnava B, Miri SM, Tabatabaei SV, Abolghasemi H, et al. Distribution of hepatitis C virus genotypes in iranian patients with congenital bleeding disorders. IRCMJ. 2010; 2010(6): 608-14
  • 19. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52(2): 421-9[DOI][PubMed]
  • 20. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, et al. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int. 2011; 31(9): 1359-65[DOI][PubMed]
  • 21. Tadokoro K, Kobayashi M, Suzuki F, Tanaka C, Yamaguchi T, Nagano M, et al. Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay. J Virol Methods. 2013; 189(1): 221-7[DOI][PubMed]
  • 22. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012; 56(6): 2134-41[DOI][PubMed]
  • 23. Moghaddam MA, Zali MR, Andabili SHA, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. IRCMJ. 2012; 14(8): 466
  • 24. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 25. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015; 21(29): 8935-42[DOI][PubMed]
  • 26. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 27. Ling Q, Chen J, Zhou H, Zhong J, Chen Y, Ye Q, et al. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms. Arch Virol. 2015; 160(4): 1105-12[DOI][PubMed]
  • 28. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010; 17(4): 236-44[DOI][PubMed]
  • 29. Azarkeivan A, Toosi MN, Maghsudlu M, Kafiabad SA, Hajibeigi B, Hadizadeh M. The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study. Transfusion. 2012; 52(8): 1814-8[DOI][PubMed]
  • 30. Hassanshahi G, Arababadi MK, Assar S, Hakimi H, Karimabad MN, Abedinzadeh M, et al. Post-transfusion-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in southeastern Iran. Arch Virol. 2011; 156(7): 1111-5[DOI][PubMed]
  • 31. Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med. 2007; 17(6): 425-33[DOI][PubMed]
  • 32. Valizadeh N, Nateghi S, Noroozi M, Hejazi S, Aghanezhad F, Ali AA. Seroprevalence of hepatitis C, hepatitis B and HIV viruses in hemophiliacs born 1985-2010 in west Azarbaijan of Iran. Asian J Transfus Sci. 2013; 7(1): 55-8[DOI][PubMed]
  • 33. Kumar D, Malik A, Asim M, Chakravarti A, Das RH, Kar P. Response of combination therapy on viral load and disease severity in chronic hepatitis C. Dig Dis Sci. 2008; 53(4): 1107-13[DOI][PubMed]
  • 34. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012; 12(3): 190-5[DOI][PubMed]
  • 35. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22(6): 696-9
  • 36. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009; 19(4): 519-23[DOI][PubMed]
  • 37. Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. Indian J Med Microbiol. 2010; 28(1): 54-6[DOI][PubMed]
  • 38. Hadinedoushan H, Salmanroghani H, Amirbaigy MK, Akhondi-Meybodi M. Hepatitis C virus genotypes and association with viral load in yazd, central province of iran. Hepat Mon. 2014; 14(3)[DOI][PubMed]
  • 39. Ross RS, Viazov S, Renzing-Kohler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol. 2000; 60(2): 122-5
  • 40. Seme K, Vrhovac M, Mocilnik T, Maticic M, Lesnicar G, Baklan Z, et al. Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993-2007. J Med Virol. 2009; 81(4): 634-9[DOI][PubMed]
  • 41. Svirtlih N, Delic D, Simonovic J, Jevtovic D, Dokic L, Gvozdenovic E, et al. Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significance. World J Gastroenterol. 2007; 13(3): 355-60[PubMed]
  • 42. Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, et al. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co‐infection. J Med Virol. 1997; 52(2): 219-25
  • 43. Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, et al. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol. 2013; 87(23): 12541-51[DOI][PubMed]
  • 44. Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, et al. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol. 2010; 82(1): 41-8[DOI][PubMed]
  • 45. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010; 53(3): 439-43[DOI][PubMed]
  • 46. Li HC, Ma HC, Yang CH, Lo SY. Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol. 2014; 20(23): 7104-22[DOI][PubMed]
  • 47. Jaspe RC, Sulbaran YF, Sulbaran MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virol J. 2012; 9: 214[DOI][PubMed]
  • 48. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005; 48(6): 372-80[DOI][PubMed]
  • 49. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol. 2011; 83(6): 1016-22[DOI][PubMed]
  • 50. Youssef SS, Abbas EA, Abd el Aal AM, Omran MH, Barakat A, Seif SM. IL28B rs 12979860 predicts response to treatment in Egyptian hepatitis C virus genotype 4 patients and alpha fetoprotein increases its predictive strength. J Interferon Cytokine Res. 2014; 34(7): 505-9[DOI][PubMed]
  • 51. Cariani E, Roli L, Missale G, Villa E, Ferrari C, Trenti T. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis. Pharmacogenomics J. 2016; 16(1): 18-29[DOI][PubMed]
  • 52. Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012; 142(4): 790-5[DOI][PubMed]
  • 53. Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, et al. HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology. 2012; 56(1): 86-94[DOI][PubMed]
  • 54. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 55. Domagalski K, Pawlowska M, Kozielewicz D, Dybowska D, Tretyn A, Halota W. The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C. PLoS One. 2015; 10(6)[DOI][PubMed]
  • 56. Younossi ZM, Birerdinc A, Estep M, Stepanova M, Afendy A, Baranova A. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med. 2012; 10: 25[DOI][PubMed]
  • 57. Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. IL28B genotype and the expression of ISGs in normal liver. Liver Int. 2013; 33(7): 991-8[DOI][PubMed]
  • 58. Tripathi LP, Kataoka C, Taguwa S, Moriishi K, Mori Y, Matsuura Y, et al. Network based analysis of hepatitis C virus core and NS4B protein interactions. Mol Biosyst. 2010; 6(12): 2539-53[DOI][PubMed]
  • 59. Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012; 47(5): 596-605[DOI][PubMed]
  • 60. Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, et al. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int. 2012; 6(1): 386-96[DOI][PubMed]
  • 61. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45
  • 62. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
  • 63. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10): 1105-9[DOI][PubMed]
  • 64. Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes & its association with viral load. Indian J Med Res. 2011; 133: 326-31[PubMed]
  • 65. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103[DOI][PubMed]
  • 66. Zheng MH, Li Y, Xiao DD, Shi KQ, Fan YC, Chen LL, et al. Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians. Gene. 2013; 518(2): 479-82[DOI][PubMed]
  • 67. Aalaei-Andabili SH, Behnava B, Salimi S, Sharafi H, Alavian SM. Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. Hepat Mon. 2014; 14(3)[DOI][PubMed]
  • 68. Alqahtani S, Sulkowski M. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. Gastroenterol Clin North Am. 2015; 44(4): 825-43[DOI][PubMed]
  • 69. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13(5): 401-8[DOI][PubMed]
  • 70. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J hepatol. 1996; 24(1): 38-47
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check